방사성 활막절제술 (Radiosynovectomy) |
Author |
김덕윤, |
Deog Yoon Kim, M.D. |
Affiliation |
경희대학교 의과대학 핵의학교실 Department of Nuclear Medicine, Kyung Hee Unversity School of Medicine, Seoul, Korea |
Abstract |
Radiosynovectomy has been used as an effective treatment in patients with resistant synovitis after failure of long-term medication and intraarticular steroid injection. Although 90Y silicate/citrate, 186Re sulfide, and 169Er citrate were approved in Europe for the appropriate radiopharmaceuticals for radiosynovectomy, other radionuclides such as 32P-chromic phosphate, 165Dy-ferric hydroxide macroaggregate, 188Rh-microspheres, 153Sm-particulate, and 166Ho- ferric hydroxide macroaggregate have been used in many countries. Reported success rates range from 40% to 90% for the different joints and underlying disease. In Korea, 188Re-tin-colloid and 166Ho-chitosan complex are now using as the major radionuclides in radiosynovectomy with good clinical results. A study on radiation synovectomy using 188Re-tin-colloid for patients with Korean rheumatoid arthritis shows the treatment resulted in the improvement of arthritis and well tolerated. In our study, the radiosynovectomy with 166Ho-chitosan complex in 53 hemophilic patients markedly decreased intra-articular bleeding frequency and need for coagulation factor.
This review inculdes general priciples in the application of radiosynovectomy and the clinical experience in Korea. (Nucl Med Mol Imaging 2006;40(2):127-131) |
Keyword |
radionuclide therapy, radiosynovectomy, rheumatoid arthritis, hemophilia |
Full text Article |
4002127.pdf
|
|
|